Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas



Status:Recruiting
Conditions:Brain Cancer, Lymphoma, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/17/2019
Start Date:October 30, 2018
End Date:August 15, 2022
Contact:Stuart A Grossman, MD
Email:jfisher@jhmi.edu
Phone:410-955-8837

Use our guide to learn which trials are right for you!

A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide

The purpose of this study is to determine the maximum tolerated dose (MTD) and select optimal
biological doses (OBD) of the study drug NT-17 in High Grade Glioma patients with severe
lymphopenia, as well as to test the effect of NT-17 on the CDR counts of patients in
comparison to control participants. This study has both a Phase I and Pilot component.

PRIMARY OBJECTIVES:

Phase I: To determine the MTD (Maximum Tolerated Dose) and select optimal biological doses
(OBD) of NT-I7 in HGG patients with severe lymphopenia

Pilot Study: To test the effect of NT-I7 on CD4 counts compared to control

SECONDARY OBJECTIVES:

1. To determine the optimal biological dose of NT-I7

2. To evaluate the effect of concurrent dexamethasone

3. To evaluate the duration of effect on CD4 counts (up to 6 months)

4. To evaluate the total lymphocyte counts over time and serial T cell lymphocyte subtypes
and the effect on T cell repertoire (up to 6 months)

5. To evaluate the serial cytokine levels (up to 6 months)

6. To evaluate the impact of adjuvant temozolomide on NT-I7 effects on CD4 counts

7. To evaluate anti-drug antibodies

8. To evaluate the pharmacokinetic profile of NT-I7 after intramuscular administration in
this patient population

9. To evaluate the safety and toxicity of NT-I7 in patients with high grade glioma

OUTLINE: Patients are assigned to 1 of 2 groups depending on their use of dexamethasone.

GROUP A: Patients not on dexamethasone (or equivalent of an alternative corticosteroid), or
on a dose lower than a physiologic dose (=< 0.75 mg daily)

GROUP B: patients who require dexamethasone (or equivalent of an alternative corticosteroid)
=> 4 mg daily

Patients must have been on the group assignment dose of corticosteroids for at least 5 days
prior to the dose of NT-I7. Corticosteroid dose changes prior to the start of treatment are
allowed as long as they do not alter patient's group assignment.

PHASE I TREATMENT PLAN

All patients (both Groups A and B) will be given a single dose of NT-I7 by intramuscular
injection starting at 60 μg/kg, within one week after completing concurrent RT+TMZ and before
starting adjuvant TMZ treatment, during the standard post-radiation break. Following this
period, as per standard treatment, patients will go on to receive adjuvant temozolomide on
Days 1-5 of 28-day cycles for 6 cycles. There should be about six weeks between the study
injection and the start of adjuvant temozolomide; thus the start of adjuvant TMZ will be
approximately two weeks later than the usual start, which is 4 weeks post-end of radiation.
Patients who are delayed from receiving or are not able to receive adjuvant TMZ treatment may
continue on study; adjuvant TMZ treatment is not a requirement for participation.

PILOT STUDY TREATMENT PLAN

GROUP A: participants will be given either a placebo (NT-I7 diluent) or one dose of NT-I7 at
the Phase I Group A OBD by intramuscular injection within one week after completing
concurrent RT+TMZ and before starting adjuvant TMZ treatment, during the standard
post-radiation break.

GROUP B: participants will be given one dose of NT-I7 at the Phase I Group B OBD by
intramuscular injection within one week after completing concurrent RT+TMZ and before
starting adjuvant TMZ treatment, during the standard post-radiation break.

After completion of study treatment, patients are followed up every 2 months for 2 years and
then every 6 months thereafter.

Inclusion Criteria:

- Patients must have histologically confirmed high grade glioma by pathology (World
Health Organization [WHO] grade III and IV)

- Patients' post-operative treatment must have included at least 80% of standard
radiation and concomitant temozolomide; patients may not have received any other
prior chemotherapy, immunotherapy or therapy with biologic agent (including
immunotoxins, immunoconjugates, antisense, peptide receptor antagonists,
interferons, interleukins, tumor infiltrating lymphocytes [TIL],
lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their
brain tumor; prior Gliadel wafers are allowed; glucocorticoid therapy is allowed

- Patients must have CD4 =< 300 cells/mm^3 in the last week (7 days) of standard
radiation + temozolomide treatment (58-60 Gy radiation with temozolomide 75 mg/m2
daily during radiation)

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Hemoglobin >= 9 g/dL

- Total bilirubin =< institutional upper limit of normal

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase
[SGPT]) =< 2.5 x institutional upper limit of normal

- Creatinine =< institutional upper limit of normal OR creatinine clearance >= 60
ml/min/1.73 m^2 for patients with creatinine levels above institutional normal

- Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT)
=< 1.5 x institutional upper limit of normal

- Patients must have a Karnofsky performance status (KPS) >= 60% (i.e. the patient
must be able to care for himself/herself with occasional help from others)

- Patients must be able to provide written informed consent

- Women of childbearing potential must have a negative serum pregnancy test prior
to study entry; women of childbearing potential and men must agree to use two
birth control methods (either two barrier methods or a barrier method plus a
hormonal method) or abstinence prior to study entry and for the duration of study
participation (through at least 90 days after the last study injection); should a
woman become pregnant or suspect she is pregnant while participating in this
study, she should inform her treating physician immediately

- Patients must have no concurrent malignancy except curatively treated basal or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast,
or bladder; patients with prior malignancies must be disease-free for >= five
years

- Dexamethasone dose must be provided for treatment group assignment:

- Group A: patients not on dexamethasone or on a dose =< 0.75 mg daily (or
equivalent of an alternative corticosteroid)

- Group B: patients who require dexamethasone >= 4 mg daily (or equivalent of
an alternative corticosteroid) ** Patients must have been on the group
assignment dose of corticosteroids for at least 5 days prior to the dose of
NT-I7; corticosteroid dose changes prior to the start of treatment are
allowed as long as they do not alter patient's group assignment

Exclusion Criteria

- Patients receiving any other investigational agents are ineligible

- Patients with known hypersensitivity to NT-I7 or any component used in the
vehicle/formulation are ineligible

- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements, are ineligible

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with NT-I7

- Patients with human immunodeficiency virus (HIV) are excluded

- Patients with a known or screening-period-determined corrected QT (QTc) interval > 450
msec and patients who require a therapy with a drug known to prolong the QT/QTc
interval, are ineligible

- Patients with a history of or who currently have evidence of autoimmune disease (other
than autoimmune thyroid disease managed with thyroid hormone replacement or vitiligo)
including: myasthenia gravis, Guillain Barre syndrome, systemic lupus erythematosus,
multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune
hepatitis, Wegener's etc., are ineligible
We found this trial at
12
sites
10833 Le Conte Avenue # 8-950
Los Angeles, California 90095
(310) 825-5268
Principal Investigator: Timothy Cloughesy, MD
Phone: 310-825-5321
Jonsson Comprehensive Cancer Center at UCLA In the late 1960s, a group of scientists and...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1802 6th Avenue South
Birmingham, Alabama 35294
(205) 934-4011
Principal Investigator: Burt Nabors, MD
Phone: 205-934-1842
UAB Comprehensive Cancer Center One of the nation’s leading cancer research and treatment centers, the...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
2010 E 90th St
Cleveland, Ohio 44195
(866) 223-8100
Principal Investigator: David Peereboom, MD
Phone: 216-444-7923
Cleveland Clinic Taussig Cancer Center At Taussig Cancer Institute, more than 250 highly skilled doctors,...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27103
(336) 716-2011
Principal Investigator: Glenn Lesser, MD
Phone: 336-713-6771
Wake Forest University Comprehensive Cancer Center Our newly expanded Comprehensive Cancer Center is the region’s...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Baltimore, Maryland 21231
Principal Investigator: Stuart A Grossman, MD
Phone: 410-955-4009
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Patrick Wen, MD
Phone: 617-632-6119
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(888) 777-4167
Principal Investigator: Tobias Walbert, MD
Josephine Ford Cancer Center at Henry Ford Hospital A diagnosis of cancer is one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Thomas Kaley, MD
Phone: 212-639-5122
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Arati Desai, MD
Phone: 800-474-9892
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: Frank Lieberman, MD
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Jian Campian, MD
Phone: 314-747-4241
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94115
?
mi
from
San Francisco, CA
Click here to add this to my saved trials